HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating restated by HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $1.00 price target on the stock. HC Wainwright’s price target indicates a potential downside of 9.09% from the stock’s previous close.

Separately, Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their price target for the company from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Stock Performance

LYEL stock opened at $1.10 on Tuesday. The company has a market capitalization of $307.14 million, a PE ratio of -1.39 and a beta of -0.47. The company’s fifty day moving average price is $1.21 and its 200-day moving average price is $1.69. Lyell Immunopharma has a one year low of $0.85 and a one year high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. The business had revenue of $0.03 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, research analysts predict that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Intech Investment Management LLC bought a new position in shares of Lyell Immunopharma in the 3rd quarter valued at about $52,000. Dimensional Fund Advisors LP lifted its stake in shares of Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after purchasing an additional 26,635 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Lyell Immunopharma in the 1st quarter worth approximately $64,000. China Universal Asset Management Co. Ltd. increased its position in shares of Lyell Immunopharma by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after purchasing an additional 19,287 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Lyell Immunopharma by 78.1% during the 3rd quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after buying an additional 25,247 shares during the period. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.